[1]Bosch FX, Ribes J.Primary liver cancer:Worldwide incidence andtrends[J].Gastroenterology, 2004, 127 (15) ∶S5-S16.
|
[2]Srivatanakul P, Sriplung H, Deerasamee S.Epidemiology of livercancer:an overview[J].Asian Pac J Cancer Prev, 2004, 5 (2) ∶118-125.
|
[3]Yao DF, Dong ZZ, Yao M.Specific molecular markers in hepato-cellular carcinoma[J].Hepatobiliary Pancreat Dis Int, 2007, 6 (3) ∶241-247.
|
[4]Pei Y, Zhang T, Ranault V, et al.An overview of hepatocellularcarcinoma study by omics-based methods[J].Acta Biochim Bio-phys Sin, 2009, 41 (1) ∶1.
|
[5]Llovet JM, Ricci S, Mazzaferro V, et al.Sorafenib in AdvancedHepatocellular Carcinoma[J].N Engl J Med, 2008, 359 (4) ∶378-390.
|
[6]Zhou L, Liu J, Luo F.Serum tumor markers for detection of hepa-tocellular carcinoma[J].World J Gastroenterol, 2006, 12 (8) ∶1175-1181.
|
[7]Gupta S, Bent S, Kohlwes J.Test characteristics of alpha-fetopro-tein for detecting hepatocellular carcinoma in patients with hepatitisC.A systematic review and critical analysis[J].Ann Intern Med, 2003, 139 (1) ∶46-50.
|
[8]Soresi M, Magliarisi C, Campagna P, et al.Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma[J].Anti-cancer Res, 2003, 23∶1747-1753.
|
[9]Grizzi F, Franceschini B, Hamrick C, et al.Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment ofhepatocellular carcinoma[J].J Transl Med, 2007, 5∶3.
|
[10]Li D, Mallory T, Satomura S.AFP-L3:a newgeneration of tumormarker for hepatocellular carcinoma[J].Clin Chim Acta, 2001, 313 (1-2) ∶15-19.
|
[11]Llovet JM, Chen Y, Wu rmbach E, et al.AMolecular Signature toDiscriminate Dysplastic Nodules From Early Hepatocellular Carcino-ma in HCV Cirrhosis[J].Gastroenterology, 2006, 131 (6) ∶1758-1767.
|
[12]Man XB, Wang HY.Upregulation of Glypican-3 expression inhepatocellular carcinoma but downregulation in cholangiocarcinomaindicates its differential diagnosis value in primary livercancers[J].Liver International, 2005, 25 (5) ∶962-966.
|
[13]Capurro M, Wanless IR, Sherman M, et al.Glypican-3:a novelserum and histochemical marker for hepatocellular carcinoma[J].Gastroenterology, 2003, 125 (1) ∶89-97.
|
[14]Hippo Y, Watanabe K, Watanabe A, et al.Identification of solubleNH2-terminal fragment of glypican-3 as a serological marker forearly-stage hepatocellular carcinoma[J].Cancer Res, 2004, 64 (7) ∶2418-2423.
|
[15]Di Tommaso L, Destro A, seok JY, et al.The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection ofhepatocellular carcinoma[J].J Hepatology, 2009, 50 (4) ∶746-754.
|
[16]Liebman HA, Furie BC, Tong MJ, et al.Des-gamma-carboxyprothrombin as a serum marker of primary hepatocellularcarcinoma[J].N Engl J Med, 1984, 310 (22) ∶1427-1431.
|
[17]Volk ML, Hernandez JC, et al.Risk factors for hepatocellular carcino-ma may impair the performance of biomarkers:a comparison of AFP, DCP, and AFP-L3[J].Cancer Biomark, 2007, 3∶79-87.
|
[18]Kladney RD, Bulla GA, Guo L, et al.A novel Golgi-localizedprotein upregulated by viral infection[J].Gene, 2000, 249 (1-2) ∶53-65.
|
[19]Spanggenberg HC, Thimme R, Blum HE.Serum Markers of Hepa-tocellular Carcinoma[J].Seminars In Liver Disease, 2006, 26 (4) ∶385-390.
|
[20]Dawson S, Higashitsaji H, Wilkinson AJ, et al.Gankyrin:a newoncoprotein and regulator of pRb and p53[J].Trends in Cell Biolo-gy, 2006, 16 (5) ∶229-233.
|
[21]Fu X, Tan L, Liu S, et al.A novel diagnostic marker, p28GANKdistinguishes hepatocellular carcinoma from potential mimics[J].JCancer Res Clin Oncol, 2004, 130 (9) ∶514-520.
|
[22]Fu XY, Wang HY, Tan L, et al.Overexpression of p28/gankyrinin human hepatocellular carcinoma and its clinical significance[J].World J Gastroenterol, 2002, 8 (4) ∶638-643.
|
[23]Li H, Fux, Chen Y, et al.Use of Adenovirus-Delivered siRNAtoTarget Oncoprotein p28GANK in Hepatocellular Carcinoma[J].Gastroenterology, 2005, 128 (7) ∶2029-2041.
|
[24]Qiu W, Wu J, Walsh EM, et al.Retinoblastoma protein modulatesgankyrin-MDM2 in regulation of p53 stability and chemosensitivityin cancer cells[J].Oncogene, 2008, 27 (29) ∶4034-4043.
|
[25]Tan L, Fu XY, Liu SQ, et al.Expression of p28GANKand its cor-relation with RB in human hepatocellular carcinoma[J].Liver In-ternational, 2005, 25 (3) ∶667-676.
|
[26]Chen Y, Li HH, Fu J, et al.Oncoprotein p28GANKbinds to RelAand retains NF-κB in the cytoplasm through nuclear export[J].Cell Research, 2007, 17 (12) ∶1020-1029.
|